NASDAQ: PRTA

Company Deals

BMS Strikes Deal with Prothena for Potential Disease-Modifying Neurology Drug PRX019

Fineline Cube May 30, 2024

Bristol Myers Squibb (BMS; NYSE: BMY) has executed an exclusive global licensing agreement with Prothena...

Policy / Regulatory

U.S. Tariffs on Pharmaceuticals and Their Impact on China’s Medical Industry

Company Drug

Sichuan Biokin Launches Phase III Trial for BL-B01D1 in Urothelial Carcinoma

Company Drug

AbbVie’s Rinvoq Approved in EU for Giant Cell Arteritis

Company Drug

Bristol-Myers Squibb’s Opdivo/Yervoy Combo Approved for MSI-H Colorectal Cancer